The other is strategic: the idea that monthly maintenance could become a mainstream dosing pattern in obesity medicine, like a contraceptive shot or a depot antipsychoticexcept tied to appetite, GI tolerance, and metabolic outcomes
What they're saying: According to the lawsuit, one of the plaintiffs switched from Zepbound to Wegovy in August after exhausting all appeals to Caremark, then "experienced a number of side effects, including the return of his Gastroesophageal Reflux Disease, stomach pain, hunger, and, most notably, weight gain." "Because of their different methods of action, different clinical outcomes, and different side effects for individual patients, Zepbound and Wegovy are not clinically interchangeable," the lawsuit states
The slowed gastric emptying caused by GLP-1 medications affects how quickly nutrients are absorbed into your bloodstream
2A, and 4-OXO-DHA metabolite in rat plasma is shown in Fig
Whats needed to fully disrupt the impact of PBMs on drug pricing, Cuban said is, That self-insured companies and states act in their own financial interests and in the wellness interest of their members by working with pass-through PBMs that allow them to get daily reports on their claims, control their formularies completely, control the [third-party administrator] rules, make sure that their local pharmacies are fully reimbursed, [and] control their network